Forsteo Is the First Bone Formation Agent Approved for Marketing Across All Member States of The European Union Lilly (NYSE:LLY) announced today that the European Commission has granted a marketing ...
Eli Lilly gibt bekannt, dass das Medikament Forsteo zur Behandlung einer bestehenden Osteoporose bei Frauen in der Postmenopause mit einem hohen Risiko für Knochenbrüche nun in den 15 Mitgliedsländern ...
Two biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada – have made their debut in Europe. Forsteo (teriparatide) – a ...
Regulators in Europe have given the go-ahead to a new indication for Eli Lilly’s blockbuster Forsteo. Regulators in Europe have given the go-ahead to a new indication for Eli Lilly’s blockbuster ...
Both products are approved in adults for osteoporosis in various indications. Richter has announced the launch of Terrosa (teriparatide) in Europe, a biosimilar of Eli Lilly’s Forsteo (teriparatide).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results